Madrigal shares skyrocket on positive NASH treatment study results
December 19, 2022 at 09:36 AM EST
The Conshohocken company expects to seek approval for its treatment of an inflammatory liver disease during the first half of 2023.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Home | News | Travel | Restaurants | Nightlife | Things To Do | Shopping | Events | Directory | Real Estate | Blog | More
|